A Phase 3 interventional study of Golidocitinib and Chidamide in Peripheral T-cell Lymphoma, sponsored by Dizal Pharmaceuticals. Recruiting at 51 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Dizal Pharmaceuticals · Phase 3, Interventional, and Treatment
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
604 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 133 are open to participants now.
This study's planned enrollment of 218 is above the median of 38 across 527 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Browse Lymphoma, T-Cell, Peripheral studies →Dizal Pharmaceuticals is the lead sponsor of 37 studies on the registry; 15 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Golidocitinib
Drug: Chidamide · Drug: Gemcitabine
150 mg, orally, once daily, with or without food, in a 21-day cycle
30 mg, orally, twice a week, with an interval of no less than 3 days in a 21-day cycle
1000 mg/m2, intravenous infusion, administered on Day 1, Day 8 and Day 15 of a 28-day cycle
Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) according to Lugano 2014
Time frame: The time from the date of randomization to the date of first progressive disease, death due to any cause whichever occurred first. Approximately 4 years.
Overall survival (OS)
Time frame: The time from randomization to death due to any cause. Approximately 4 years.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dizal Pharmaceuticals